Navigation Links
VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
Date:10/10/2007

SHP-1 & SHP-2) and PTB-1B, based on data from several preclinical studies conducted at the Cleveland Clinic. These intracellular enzymes are involved in signaling pathways of many receptor-linked tyrosine kinases which are involved in growth, proliferation and differentiation of cancer cells. Inhibition of these enzymes with Lenocta(TM) can trigger apoptosis, (programmed cell death) of malignant cells. This antiproliferative and pro-apoptotic effects, coupled with its potential ability to enhance the body's immune system, through improved cytokine signaling, T-cell and dendritic cell functions indicate that Lenocta(TM) has potentials as an anti-cancer agent. It is known that one major mechanism of regulating the growth and proliferation of cancer cells involves activation of cellular pathways, especially protein tyrosine kinase pathways and in particular, the Jak/Stat pathway. It has also been recognized that interferon and other cytokines exert their anti-cancer effects via these pathways.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits activation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases (PTPases), SHP-1 and SHP-2, which has shown compelling clinical and biological activity in solid tumors and Xyfid(TM), a topical therapy which has shown early clinical promise in the treatment and prevention of chemo-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing several Phase II trials for VQD-002, Lenocta(TM) and Xyfid(TM) in the second half of 2007. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, ... EURONEXT: SAN) and the life sciences team at Google ... and outcomes for people with type 1 and type ... and devices with Google,s expertise in analytics, miniaturized electronics ... how to improve diabetes care by developing new tools ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
(Date:8/31/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... August ... ... Movestrong, has launched a new weight management program that is unique to the ... recommended programs in Oakland and Macomb County. , WEmovestrong’s weight management program ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is ... from 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, located at ... Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... practice! Garden State Urology was formed in 2008, the result of a merger ... the principle that by working cooperatively, they could provide more cost-effective and higher ...
(Date:8/31/2015)... ... ... FCPX LUT Soft pack from Pixel Film Studios, editors can quickly and easily add soft ... for modifying an image. The LUT changes every pixel's color to the corresponding color indicated ... Soft requires Final Cut Pro X 10.2 or newer. , By manipulating each pixel, ...
(Date:8/31/2015)... Ana, CA (PRWEB) , ... August 31, 2015 ... ... for the 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards ... the Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... readmissions, provided timely intervention , , THURSDAY, May 1 ... condition of mobile heart failure patients and may ... that included 150 patients admitted to Massachusetts General ... 70, were randomly selected to receive usual care ...
... elsewhere report what is believed to be the first ... heart tissue and the subsequent damage leading to failure ... from the Multiethnic Study of Atherosclerosis (MESA), to be ... of the American College of Cardiology, appear to nail ...
... Children,s Hospital UCLA have found that low-dose antidepressant therapy can ... from irritable bowel syndrome, or IBS. , ... 14 percent of high school kids in the United States. ... issue of the peer-reviewed Journal of Pediatrics, is the first ...
... today,released the following statement in support of the ... afternoon by an,overwhelming 414 to 1 vote. The ... employers from discriminating against people on the,basis of ... desk for his,signature. Below are the Speaker,s remarks, ...
... Edward G.,Rendell said today that there are more than ... 5,000 of whom are on a waiting,list to receive ... Senate,to approve a plan to help them gain access ... Pennsylvania adults live with the,very real fear that a ...
... has received a,one-year grant of $150,000 from the ... Bridge to Independence. This coordinated campaign works to,improve ... disabilities,through effective grassroots community organizing, policy advocacy, civic,engagement ... of the Minnesota Consortium of Citizens with,Disabilities (MN-CCD), ...
Cached Medicine News:Health News:Home Monitoring Program Improves Outcomes for Heart Patients 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents 2Health News:Pelosi: 'Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information' 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 3Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 4Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 5Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 6Health News:Courage Center Receives $150,000 Grant From Minneapolis Foundation 2
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... With a zoom ratio of ... 0.75X to 11.25X, and the ... intervals from 1X to 11X, ... Magnifications of 3.75X to 540X ...
Inquire...
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
Medicine Products: